Detalhe da pesquisa
1.
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
Nature
; 596(7871): 268-272, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34107529
2.
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.
N Engl J Med
; 386(9): 847-860, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35139271
3.
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
N Engl J Med
; 384(23): 2187-2201, 2021 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33882225
4.
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
N Engl J Med
; 384(19): 1824-1835, 2021 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33440088
5.
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine.
Ann Intern Med
; 174(5): 585-594, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33587687
6.
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.
JAMA
; 325(15): 1535-1544, 2021 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33704352
7.
Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination.
N Engl J Med
; 385(10): 951-953, 2021 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34260834
8.
Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
JAMA
; 315(15): 1610-23, 2016 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-27092831
9.
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Infect Dis
; 22(12): 1703-1715, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36113538
10.
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.
NPJ Vaccines
; 7(1): 156, 2022 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36450746
11.
Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
Vaccine
; 40(32): 4403-4411, 2022 07 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35667914
12.
Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19.
medRxiv
; 2021 Jul 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34268527
13.
Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.
Health Secur
; 18(3): 241-249, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32348165